Clopidogrel
Product Images NDC 0615-8014

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 0615-8014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopiodgrel-01 (Clopidogrel 75mg Apotex 1)

Chemical structure of clopidogrel sulfate showing its molecular framework including the thiophene ring, piperidine ring, methoxycarbonyl group, and chlorine-substituted phenyl ring.*

FDA Label Image

Clopidogrel Tebs 75mg Bingo Label (Clopidogrel 75mg Apotex 10)

Label for Clopidogrel Tablets, USP 75 mg by NCS HealthCare of KY, LLC dba Vangard Labs, manufactured by Apotex. The label includes the product name, strength, dosage form, quantity of 30 tablets, lot number 8014, barcodes, storage instructions at controlled room temperature, and a dosage information note for institutional use only.*

FDA Label Image

Clopidogrel Tabs 75mg Unit-dose Label (Clopidogrel 75mg Apotex 11)

Label sheet for Clopidogrel Tablets USP 75 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The sheet contains multiple small labels showing the drug name, strength, tablet form, lot number 8014, and a barcode. The bottom of the sheet has a larger information label indicating a quantity of 30 tablets, prescription use, storage instructions, manufacturer Apotex, and repackaging by Vangard Labs in Glasgow, KY.*

FDA Label Image

Figure-01 (Clopidogrel 75mg Apotex 2)

A figure titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel 75 mg Alone or with Proton Pump Inhibitors (PPIs)'. The chart shows the effect on active metabolite AUC with mean and 90% confidence intervals for Clopidogrel administered alone compared to co-administration with four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The horizontal axis represents change relative to Clopidogrel administered alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure2 (Clopidogrel 75mg Apotex 3)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rates (%) over 12 months of follow-up. Two lines compare placebo (+ aspirin) and clopidogrel (+ aspirin) groups, with the clopidogrel line consistently lower. The p-value 0.00009 is noted, indicating statistical significance.*

FDA Label Image

Figure-03 (Clopidogrel 75mg Apotex 4)

A forest plot figure titled 'Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study' showing hazard ratios with 95% confidence intervals. The plot compares Clopidogrel with placebo across various patient baseline characteristics and concomitant medications, indicating percent events and whether Clopidogrel or placebo had better outcomes. Patient groups include diagnosis types, age, gender, race, cardiac enzyme elevation, diabetes, previous myocardial infarction or stroke, and use of other medications such as heparin, aspirin, beta-blockers, ACE inhibitors, and lipid-lowering therapies.*

FDA Label Image

Figure4 (Clopidogrel 75mg Apotex 5)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing the percentage of deaths before first discharge over 28 days since randomization. The graph compares two groups: Placebo with 1845 deaths (8.1%) and Clopidogrel with 1726 deaths (7.5%), indicating a 7% proportional risk reduction (p=0.03) for Clopidogrel.*

FDA Label Image

Figure5 (Clopidogrel 75mg Apotex 6)

A cumulative event rate curve from the COMMIT study showing percentage of patients with death, re-infarction, or stroke before first discharge over 28 days of randomization. Two lines compare placebo (10.1% events) and Clopidogrel (9.2% events), indicating a 9% proportional risk reduction with Clopidogrel. The x-axis represents days since randomization, and the y-axis represents percentage of patients with events.*

FDA Label Image

Figure6 (Clopidogrel 75mg Apotex 7)

A forest plot chart illustrating the effects of adding Clopidogrel to Aspirin on the combined primary endpoint across various baseline and concomitant medication subgroups in the COMMIT study. It compares event percentages and odds ratios between Clopidogrel and placebo cohorts by demographic and clinical factors such as sex, age, blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation, including confidence intervals and heterogeneity p-values.*

FDA Label Image

Figure7 (Clopidogrel 75mg Apotex 8)

A forest plot illustrating the effects of adding Clopidogrel to Aspirin in non-prespecified subgroups from the COMMIT study. The chart compares event percentages and odds ratios with confidence intervals for Clopidogrel versus placebo across various categories, including Killip class, previous myocardial infarction status, and interaction location, along with heterogeneity p-values.*

FDA Label Image

Figure8 (Clopidogrel 75mg Apotex 9)

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' showing cumulative event rates over months of follow-up up to 36 months. Two lines represent the event rates for Aspirin and Clopidogrel, with Clopidogrel showing a slightly lower cumulative event rate than Aspirin. The graph includes a p-value of 0.045 indicating statistical comparison.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.